Highest-materiality recent filing
Janux Therapeutics CMO Dr. William Go departs; no impact on clinical timelines
CMO William Go, M.D., Ph.D. departed June 23, 2026; company determined termination without Cause under severance plan.
Janux Therapeutics shareholders elect directors, ratify auditor, approve Say-on-Pay at 2026 meeting
Natasha Hernday and Eric Dobmeier elected as Class II directors; Hernday received 42.85M votes for, Dobmeier 46.28M.
Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014
Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes
On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.
Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront
Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones
Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.
Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues
Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.
Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025
Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.
Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered
Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.
Janux Therapeutics shareholders elect three Class I directors, ratify EY
David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.
Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC
Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data
Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.
Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants
Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999
Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end
Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.
Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone
Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.
Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.
Janux shareholders elect three Class III directors and ratify EY as auditor
Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.
Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing
Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data
Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants
Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
Janux Therapeutics suspends ATM equity offering program
Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.
Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M
At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.
Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors
JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.
Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027
Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.
Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained
Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.
Janux Therapeutics prices $60M underwritten offering of common stock and pre-funded warrants
Priced 4,153,717 shares at $12.46/share and pre-funded warrants for 583,483 shares at $12.459 each.
Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients
Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.
Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead
Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.
Janux loses majority-independent board after director exit; Nasdaq grants cure period
Independent director Peter Thompson did not stand for re-election, reducing independent directors to 4 out of 9 total.
Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1
Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.
Janux Therapeutics enters into $150M ATM equity offering agreement with BofA
Up to $150M in common stock may be sold at the company's discretion through BofA as sales agent or principal.
Director Peter Thompson to not stand for re-election at Janux 2023 annual meeting
Peter Thompson, M.D., informed Janux he will not stand for re-election to the Board at the 2023 annual meeting due to competing commitments.
Janux Therapeutics posts 2022 net loss of $63.1M; cash at $327M; JANX007 update expected 2H 2023
Net loss of $63.1M for FY2022, vs $32.7M in FY2021; R&D expenses doubled to $53.4M.
Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial
Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).
Janux appoints Winston Kung to board; Stefan Heller resigns
Winston Kung appointed as Class I director, term expiring at 2025 annual meeting, effective Sept 21, 2022.
Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007
Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.
Janux Therapeutics stockholders elect three Class I directors, ratify auditor at 2022 annual meeting
David Campbell, Ron Barrett, and Stefan Heller elected as Class I directors with 33.9M, 34.7M, and 33.9M votes for, respectively.
Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007
Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.
Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference
Management presented two posters at PEGS Boston on May 2-5, 2022.
Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.
Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022
Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.
Janux Therapeutics enters 126-month lease for ~47,300 sq ft lab/office space in San Diego
Lease for 47,300 sq ft at 10955 Vista Sorrento Pkwy, San Diego; commencement July 1, 2022.
Janux Therapeutics appoints Ronald Barrett and Alana McNulty as directors
Ronald Barrett, Ph.D. appointed as Class I director with term expiring at 2022 annual meeting.
Janux enters 13-month lease for San Diego office space at ~$22k/month
Leased 7,432 sq ft at 10590 West Ocean Air Dr, San Diego, CA.
Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO
Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.
Janux Therapeutics increases CEO base salary to $500k, bonus target to 50%
CEO David Campbell's annual base salary increased from $424,408 to $500,000 effective July 15, 2021.
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.
On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.
On March 27, 2023, Peter Thompson, M.D., a director of Janux Therapeutics, Inc. (the “Company”), informed the Company that he does not intend to stand for re-election as a member of the Board of Directors at the Company’s 2023 annual meeting of stockholders as a result of competing commitments.
Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.
On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company
appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
Max materiality 0.90 · Median 0.60 · Most common event earnings